Next Generation Drug Discovery at Fulcrum Therapeutics: FTX-6058, A Novel EED Inhibitor To Increase Fetal Hemoglobin Expression For the Treatment of Select Hemoglobinopathies

Time: 2:30 pm
day: Day Two


• Fulcrum Therapeutics identifies drug candidates to treat rare genetic
diseases at their root cause
• FulcrumSeek as a next generation Product Engine for drug discovery
• Case Study 1: Discovery of FTX-6058, a novel EED inhibitor to increase
fetal hemoglobin for the treatment of select hemoglobinopathies